AIM ImmunoTech
9 hedge funds and large institutions have $307K invested in AIM ImmunoTech in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
18% less funds holding
Funds holding: 11 → 9 (-2)
47% less capital invested
Capital invested by funds: $578K → $307K (-$270K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$173K |
| 2 |
Renaissance Technologies
New York
|
+$8.68K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$301K |
| 2 |
Morgan Stanley
New York
|
-$72.2K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$9K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.51K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$393 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $288K | +$173K | +3,439 | +185% |
|
|
2
Renaissance Technologies
New York
| $9K | +$8.68K | +173 | New |
|
3
BlackRock
New York
| $6K | – | – | – |
|
|
4
Bank of America
Charlotte,
North Carolina
| $2K | -$3.51K | -70 | -69% |
|
|
5
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$2.21K | +44 | New |
|
|
APA
6
American Portfolios Advisors
Holbrook,
New York
| $124 | – | – | – |
|
|
AFM
7
Anson Funds Management
Dallas,
Texas
| – | -$393 | -5,156 | Closed |
|
|
8
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$301K | -3,953 | Closed |
|
|
9
Morgan Stanley
New York
| – | -$72.2K | -1,439 | -100% |
|
|
ARTA
10
A.R.T. Advisors
New York
| – | -$9K | -124 | Closed |
|
AIM Hedge Fund Activity: Q4 2019 in Review
9 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q4 2019, worth a combined $307K — down 47% from $578K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AIM and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, adding an estimated $173K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $301K sold.
- 9 institutional investors held AIM ImmunoTech (AIM) as of Q4 2019, down from 11 in Q3 2019.
- Funds reported $307K of AIM ImmunoTech stock for Q4 2019, down 47% quarter-over-quarter.
- 2 funds opened new AIM ImmunoTech positions in Q4 2019 and 4 closed out, a net change of -2 holders.
- The largest AIM ImmunoTech buyer in Q4 2019 was Sabby Management, an estimated $173K added.
- The largest AIM ImmunoTech seller in Q4 2019 was Hudson Bay Capital Management, an estimated $301K sold.
Based on aggregated 13F filings for Q4 2019.